AI-based drug discovery firm BenevolentAI cuts SPAC deal

AI-based drug discovery firm BenevolentAI cuts SPAC deal

Source: 
Pharmaforum
snippet: 

UK artificial intelligence specialist BenevolentAI has said it will float on the Amsterdam Euronext exchange in what is being touted as Europe’s largest ever special purpose acquisition company (SPAC) deal.